Oral Biologics Opportunity Intract Pharma focuses on converting injectable biologics into oral tablets using Phloral and Soteria technologies, presenting a clear path to expand patient access and adherence for autoimmune and GI inflammatory diseases. Potential sales angle: partner with contract manufacturers, payer strategies, and pharmaceutical companies seeking patient-friendly formulations.

Strategic Partnerships The company has a history of licensing and collaboration with industry players (Tharimmune, Bio-Thera Solutions, Celltrion, Elasmogen) to co-develop oral monoclonal antibodies. Sales opportunity lies in pursuing co-development or licensing deals with biopharma seeking to augment their portfolios with oral biologics to address GI and systemic inflammatory indications.

Target Indications Core focus areas include inflammatory bowel disease and other immune-mediated inflammatory diseases with systemic implications. Market potential exists for partnerships targeting gastroenterology clinics, specialized treatment centers, and CROs involved in autoimmune disease trials to accelerate clinical programs leveraging oral formats.

Global Footprint Based in London with collaborations across international partners, there is room to expand business development in Europe and beyond. Opportunities include licensing to regional manufacturers, distribution agreements, and regulatory strategy support for multi-country trials and commercialization.

Manufacturing & Scale Soteria technology emphasizes scalable manufacturing for oral antibody products, backed by Innovate UK funding. Potential upsell lies in offering manufacturing services, process development, and technology transfer partnerships to biotech firms exploring oral biologics, accelerating time-to-market and reducing development risk.